Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005594 · ClinicalTrials.gov registry record · Phase 2
ISIS 2503 in Treating Patients With Advanced Cancer of the Pancreas
A Phase 2 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT00005594 is a Phase 2 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 4 participants.
The verdict
NCT00005594, a Phase 2 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ISIS 2503 in treating patients who have advanced cancer of the pancreas.
Interventions
- DRUG ISIS 2503
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2000-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005594
The ClinicalTrials.gov registry entry for NCT00005594 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ISIS 2503 is the first listed.
NCT00005594 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005594 about?
NCT00005594 is a clinical study titled "ISIS 2503 in Treating Patients With Advanced Cancer of the Pancreas". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ISIS 2503 in treating patients who have advanced cancer of the pancreas.
What is the current status of trial NCT00005594?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2000-07.
What interventions are being tested in trial NCT00005594?
The interventions under investigation include: ISIS 2503 (DRUG).
Who is sponsoring clinical trial NCT00005594?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.